Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04529434
Other study ID # MAL19012
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 4, 2022
Est. completion date December 31, 2025

Study information

Verified date March 2024
Source University of Oxford
Contact Lorenz von Seidlein, Ass.Prof.
Phone 66 9 2648-6322
Email Lorenz@tropmedres.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Malaria, pneumonia and diarrhoea causes a lot of illness in children in Tanzania and the study want to find better ways of protecting people against these diseases and want to find out if the type of house design can affect the general health of children living in the house.


Description:

The study hypothesis is that healthy houses will reduce the incidence of malaria, respiratory diseases and diarrhoeal diseases in children compared with traditional houses. And healthy houses are also likely to reduce the incidence of all-cause morbidity incidence, disease severity, improve growth and well-being. The primary endpoints will be assessed in children under 13 years of age through weekly household visits for three years. All homes will have access to basic vector control, such as insecticide treated nets (ITNs). Access to early diagnosis and appropriate malaria treatment will be assured. Approximately 2,750 Tanzanians living in 550 houses in Mtwara region, of which 110 are new design houses (Star Homes) and the remaining 440 traditional African houses will be participating in this study. 330 children living in the novel design houses and 1320 children in traditional homes will be followed for three years for the assessment of malaria, respiratory tract infections and diarrhoea. Mosquito density will be assessed from all 550 houses where tent/light trap will be used for mosquito catch at night in all study houses. Acceptance of the novel designed houses will be assessed using mixed methods. Acceptability surveys will be conducted with 550 household heads concurrently with in-depth interviews with 30 purposively selected heads of the households in the intervention arm. Ten focus group discussions will be conducted each comprising 10 heads of households making it to be 100 heads of households. Funder: Hanako Foundation, Singapore


Recruitment information / eligibility

Status Recruiting
Enrollment 2750
Est. completion date December 31, 2025
Est. primary completion date January 3, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 12 Years
Eligibility Inclusion Criteria Main study - Children, aged under 13 years old, male or female - Residing in a study village for at least 3 years - Parents/guardian is willing and able to give written informed consent for the child to participate in the baseline and end-of study evaluation and the surveillance for malaria, respiratory tract infection and diarrhoeal disease. - Additionally, children 10, 11, and 12 years of age provide assent to participate. Ancillary studies - Head of a household or other family member of a household that is taking part in the main study - 18 years and above - Consent to take part in the main study - Residing and live in the village for 3 years or more - Live in the intervention or comparison houses or a trusted community member (community leaders, medical officer and community health worker) Exclusion criteria Main study - Any participant who refuses, or in the case of children whose parents/guardian refuses, to participate in the study. - Any child who is between 10 and 12 years who refuses to provide assent - If the family plans for moving to other village during the study period - Parents/guardians have mental health problems Ancillary studies - Under 18 years - Not provide consent - Not living in the study village for 3 years or more

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Star Homes
110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight & durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
Traditional African houses
A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.

Locations

Country Name City State
Tanzania CSK Research Solutions Dar Es Salaam Mtwara

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford CSK Research Solutions, Mahidol Oxford Tropical Medicine Research Unit

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of malaria in children under 13 years of age. The incidence per year of malaria in children under 13 years old. Approximately 3 years
Primary Incidence of respiratory tract disease in children under 13 years of age. The incidence per year of respiratory tract disease in children under 13 years old. Approximately 3 years
Primary Incidence of diarrhoeal disease in children under 13 years of age. The incidence per year of diarrhoeal disease in children under 13 years old. Approximately 3 years
Secondary Mean number of female An. gambiae s.l. Mean number of female An. gambiae s.l./light trap/night Approximately 3 years
Secondary Mean number of flies Mean number of flies/sticky trap/week in kitchens of the houses Approximately 3 years
Secondary Entomological inoculation rate of malaria vectors. Compare entomological inoculation rate of mosquito inside novel and traditional rural houses. Approximately 3 years
Secondary Children requiring hospital admission Compare hospitalization rate of children under 13 years living inside novel and traditional rural houses. Approximately 3 years
Secondary Major respiratory pathogens From children requiring hospital admission, the most frequently detected respiratory tract pathogens will be assessed through blood culture. Approximately 3 years
Secondary Major enteric pathogens From children requiring hospital admission, the most frequently detected enteric pathogens will be assessed through rotavirus ELISA testing and bacterial culture of stool specimens. Approximately 3 years
Secondary Prevalence of malaria parasitaemia among children living in novel design houses and traditional homes. Prevalence will be assessed from a cross-sectional surveys of children, based on dried blood smears will be collected for quantitative polymerase chain reaction once per quarter. Approximately 3 years
Secondary Mean changes in weight Weight in kilograms of children under 13 years of age recorded at baseline, annually and at end of the study. Approximately 3 years
Secondary Mean changes in height Height in meters of children under 13 years of age recorded at baseline, annually and at end of the study. Approximately 3 years
Secondary Mean changes in body mass index (BMI) BMI in Kg/m2 in meters of children under 13 years of age recorded at baseline, annually and at end of the study. Approximately 3 years
Secondary Mean changes in mid-upper arm circumference Mid-upper arm circumference in millimeters of children under 13 years of age recorded at baseline, annually and at end of the study. Approximately 3 years
Secondary Disease severity A subgroup analysis of children requiring hospital consultation and children requiring hospitalization. Approximately 3 years
Secondary Indoor temperature Temperature will be measured using data loggers. Approximately 2 years
Secondary Humidity Humidity will be measured using data loggers. Approximately 2 years
Secondary Carbon dioxide (CO2) Carbon dioxide (CO2) will be measured using data loggers. Approximately 2 years
Secondary Particulate matter 2.5 (PM2.5) particle pollution PM2.5 particle pollution will be measured using data loggers. Approximately 2 years
Secondary Acceptability of the novel design houses. The acceptability will be measured through a mixed method: 1) quantitative method i.e. closed ended questions with a pre-determined set of choices 2) qualitative method i.e. open ended questions through focused group discussions and in-depth interviews. Interviews at 6 months after moving in, 1 year and at the end of the study
Secondary Bednet use Assessed by asking residents and in children with less than 5 years old in traditional and novel design homes regarding the use of insecticide treated bednets. Annually (for three years)
Secondary Life-cycle analysis This is the cost of illness averted by living in a novel-designed home against a background of complete coverage with insecticide-treated nets. The analysis will include cost comparison (construction and maintenance of novel and control houses) and market analysis. Over 36 months period starting from moving in date.
Secondary Durability Yearly inspections of houses (control and intervention). Maintenance of structural problems on demand. End of year 1, 2 and 3.
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02315690 - Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland Phase 3